MannKind Corp. MNKD gained in Tuesday's extended session after the drug company posted a fourth-quarter loss in line with expectations and said operating expense fell 35 percent.
Shares of the Valencia, California development-stage company changed hands recently at $7, up more than 4 percent.
Mannkind posted a net loss of $36.4 million, or $0.09 a share, versus a year-earlier net loss of 53.6 million, or $0.16 a share.
Wall Street expected a loss of $0.09 a share.
ALthough revenue was negligible, the company noted that it launched its Afrezza inhalable insulin in the fourth quarter, and said operating expenses declined 35 percent from a year earlier on lower research and development costs.
General and administrative costs declined 29 percent, mainly on lower non-cash compensation expenses.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.